ERBB2 and cancer: Patients with cancers of high TILs are more likely to show good responses to neoadjuvant chemotherapy and immunotherapy, particularly in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative (TN) breast cancer, and have improved progression-free survival [5,7,8].